Cargando…
A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263591/ https://www.ncbi.nlm.nih.gov/pubmed/22287956 http://dx.doi.org/10.1155/2012/260643 |
_version_ | 1782221890816835584 |
---|---|
author | Vereecken, Pierre Cornelis, Frank Van Baren, Nicolas Vandersleyen, Valérie Baurain, Jean-François |
author_facet | Vereecken, Pierre Cornelis, Frank Van Baren, Nicolas Vandersleyen, Valérie Baurain, Jean-François |
author_sort | Vereecken, Pierre |
collection | PubMed |
description | Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body fluids such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum biomarkers of melanoma progression and metastatic disease are still awaited in order to provide efficient rationale for followup and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma patients. However, the poor sensitivity and specificity of those markers and many other molecules are serious limitations for their routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology and proteomic research will surely provide new candidates in the near future allowing more accurate definition of the individual prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies. |
format | Online Article Text |
id | pubmed-3263591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32635912012-01-27 A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients Vereecken, Pierre Cornelis, Frank Van Baren, Nicolas Vandersleyen, Valérie Baurain, Jean-François Dermatol Res Pract Review Article Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body fluids such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum biomarkers of melanoma progression and metastatic disease are still awaited in order to provide efficient rationale for followup and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma patients. However, the poor sensitivity and specificity of those markers and many other molecules are serious limitations for their routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology and proteomic research will surely provide new candidates in the near future allowing more accurate definition of the individual prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies. Hindawi Publishing Corporation 2012 2012-01-12 /pmc/articles/PMC3263591/ /pubmed/22287956 http://dx.doi.org/10.1155/2012/260643 Text en Copyright © 2012 Pierre Vereecken et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Vereecken, Pierre Cornelis, Frank Van Baren, Nicolas Vandersleyen, Valérie Baurain, Jean-François A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title | A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title_full | A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title_fullStr | A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title_full_unstemmed | A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title_short | A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients |
title_sort | synopsis of serum biomarkers in cutaneous melanoma patients |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263591/ https://www.ncbi.nlm.nih.gov/pubmed/22287956 http://dx.doi.org/10.1155/2012/260643 |
work_keys_str_mv | AT vereeckenpierre asynopsisofserumbiomarkersincutaneousmelanomapatients AT cornelisfrank asynopsisofserumbiomarkersincutaneousmelanomapatients AT vanbarennicolas asynopsisofserumbiomarkersincutaneousmelanomapatients AT vandersleyenvalerie asynopsisofserumbiomarkersincutaneousmelanomapatients AT baurainjeanfrancois asynopsisofserumbiomarkersincutaneousmelanomapatients AT vereeckenpierre synopsisofserumbiomarkersincutaneousmelanomapatients AT cornelisfrank synopsisofserumbiomarkersincutaneousmelanomapatients AT vanbarennicolas synopsisofserumbiomarkersincutaneousmelanomapatients AT vandersleyenvalerie synopsisofserumbiomarkersincutaneousmelanomapatients AT baurainjeanfrancois synopsisofserumbiomarkersincutaneousmelanomapatients |